Free Trial
NASDAQ:KPRX

Kiora Pharmaceuticals Q3 2024 Earnings Report

Kiora Pharmaceuticals logo
$2.39 0.00 (0.00%)
As of 10:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kiora Pharmaceuticals EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.90
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Kiora Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kiora Pharmaceuticals Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Friday, November 8, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Kiora Pharmaceuticals' Q3 2025 earnings is scheduled for Friday, August 8, 2025

Earnings Documents

Kiora Pharmaceuticals Earnings Headlines

Kiora Pharmaceuticals (KPRX) to Release Earnings on Friday
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
See More Kiora Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kiora Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiora Pharmaceuticals and other key companies, straight to your email.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals (NASDAQ:KPRX), a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

View Kiora Pharmaceuticals Profile

More Earnings Resources from MarketBeat